0000012208false00000122082024-04-102024-04-100000012208us-gaap:CommonClassAMember2024-04-102024-04-100000012208us-gaap:CommonClassBMember2024-04-102024-04-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: April 10, 2024
(Date of earliest event reported)
BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 1-7928
|
|
|
|
|
|
|
|
|
| Delaware |
|
94-1381833 |
| (State or other jurisdiction of incorporation) |
|
(I.R.S. Employer Identification No.) |
1000 Alfred Nobel Dr.
Hercules, California 94547
(Address of principal executive offices, including zip code)
(510)724-7000
(Registrant’s telephone number, including area code)
|
|
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
|
|
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities registered pursuant to Section 12(b) of the Act: |
|
|
|
|
|
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Class A Common Stock, Par Value $0.0001 per share |
|
BIO |
|
New York Stock Exchange |
| Class B Common Stock, Par Value $0.0001 per share |
|
BIO.B |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
|
|
|
|
|
|
|
|
|
Emerging growth company |
☐ |
|
|
|
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
☐ |
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 10, 2024, Dr. Andrew Last, the Executive Vice President, Chief Operating Officer (and principal operating officer) of Bio-Rad Laboratories, Inc. (the “Company”), notified the Company that he intends to retire from his position by early September 2024. In order to ensure a smooth transition, Dr. Last will remain in his current position while the Company conducts a search for his successor.
A copy of the press release announcing the retirement of Dr. Last is furnished with this report as Exhibit 99.1.
ITEM 9.01 Financial Statements and Exhibits
|
|
|
|
|
|
|
|
|
Exhibit
Number |
|
Description |
| 99.1 |
|
|
| 104.1 |
|
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
BIO-RAD LABORATORIES, INC. |
| |
|
|
|
|
| Date: |
April 10, 2024 |
|
By: |
/s/ Norman Schwartz |
| |
|
|
|
Norman Schwartz |
| |
|
|
|
President and Chief Executive Officer |
EX-99.1
2
bio-8k4102024xex991.htm
EX-99.1
Document
Exhibit 99.1
Press Release
Bio-Rad's Chief Operating Officer Andrew Last to Retire
HERCULES, Calif.— April 10, 2024 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of Bio-Rad’s executive leadership team to ensure a smooth transition while the company conducts a search for his successor.
Dr. Last joined Bio-Rad in April of 2019 with over 30 years of experience in global operations management spanning the life sciences.
“Andy’s extensive operations experience, technical acumen, and leadership abilities have been invaluable to Bio-Rad over the past five years,” said Norman Schwartz, Bio-Rad President and CEO. “We have made significant progress on our transformational objectives, including cost structure, core processes, and supply chain improvements, while effectively navigating various macroeconomic challenges.”
Dr. Last stated, “When I reflect on my tenure at Bio-Rad, I am most proud of the team we have built and the operations and management systems we have put in place. I am confident that these accomplishments have positioned Bio-Rad well for the next phase of its continued journey of transformation and growth.”
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
Investor Contact:
Edward Chung, Investor Relations
510-741-6104
ir@bio-rad.com
Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
cc@bio-rad.com
エドガーで原本を確認する